1 September 2024

Clinical trial update (ASX Announcement)

Melbourne, Australia; 27 June 2023: A voluntary partial clinical hold has been implemented on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419). This Phase 1/2 study is in the dose escalation phase.

The asymptomatic reported events leading to the voluntary partial hold were assessed as not related to Starpharma’s DEP® dendrimer. The voluntary partial clinical hold does not impact
Starpharma’s platform technology, or other clinical DEP® programs or partnerships.

The other clinical study of AZD0466 in patients with non-Hodgkin’s lymphoma (NCT05205161) is not impacted and continues to enroll patients.


Starpharma will provide further details to the market when additional relevant information becomes available. AstraZeneca (LSE/STO/Nasdaq: AZN) is the study sponsor.

View or download the ASX Announcement here.

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.